Mahévas, et al. (2020) [38]  No-randomize clinical study181 COVID-19 infected patients  HCQ group -> 600 mg/day for 5 days (n = 84) within 48 h of admission to hospitalControl group (n = 97)  Within day 7:20.2% infected patients of the HCQ group and 22.1% in the control group died or were transferred to the ICU;27.4% of the HCQ group and 24.4% of the no-HCQ group shown acute respiratory distress;On day 7 the percentage of death was similar in both HCQ and control group (2.8 vs. 4.8%, 3 vs. 4 events)  7 patients of the HCQ group showed QT interval prolongation.One patient presented first-degreeatrioventricular block after 2 days of HCQ administration.  The study was not randomized.Potential unmeasured confounders may bias the results.